Incidence and survival in late liver metastases of colorectal cancer

Abstract

Liver metastases from colorectal cancer remain a substantial problem and continue to occur long after five years. This study furnishes unbiased figures that can be used as a reference. Liver metastases that appear late have a better prognosis.

Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer

“…Patients with metachronous tumours treated 1⋅54-7⋅12 years after diagnosis had a better prognosis, in accordance with other reports 47 . Patients with metastases that were treated surgically 0⋅76-1⋅54 years after diagnosis of the primary tumour had the worst outcome.…”

Therapy of primary and metastatic liver cancer by human iPS cell‐derived myeloid cells producing interferon‐β

“…Patients with many types of cancer are at high risk of liver metastases. Moreover, tumors originating from intra‐abdominal organs, such as those of the stomach, pancreas, colon, gallbladder, bile duct, and ovary, often exhibit both peritoneal dissemination and liver metastasis . Together with the findings of our previous study , the results obtained in this study suggest that the i.p.…”

Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway

“…The selection criteria for surgery have expanded, and patients with limited concomitant extrahepatic disease are now also offered surgery. Several region‐based studies have published resection rates for CLM, with values between 6 and 35 per cent. Three nationwide studies have been conducted in recent years.…”

“…Colorectal cancer is the second most common malignancy in Norway with approximately 4000 patients diagnosed annually. A substantial proportion of patients with colorectal cancer (15–29 per cent) develop colorectal liver metastases (CLM), and surgery is the only treatment with curative intent. Improvements in surgical technique, better insight into the biology of the disease, and the development of potent chemotherapeutic and targeted drugs have expanded the indications for surgery.…”

“…In patients denied surgery, oncological treatment has prolonged survival for up to 2–3 years after the diagnosis of CLM. Until recently, information on resection rates in patients with CLM was limited.…”